Profile data is unavailable for this security.
About the company
Eris Lifesciences Limited is an India-based pharmaceutical company. The Company is engaged in the manufacture and marketing of pharmaceutical products. The Company has a presence in major therapies like oral anti-diabetes, insulins, cardiovascular, vitamins/minerals and dermatology. Its flagship therapies include oral anti-diabetes, cardiovascular disease (CVD), and vitamins, minerals and nutrients (VMN). Its emerging therapies consist of dermatology, insulins, women’s health, central nervous system (CNS), oncology, and nephrology. Its portfolio of brands includes Glimisave, Eritel, LNBloc, Olmin, Crevast, Atorsave, Gluxit, Renerve, Zomelis, Cosvate, Tayo, Cyblex, Remylin, Tendia, Rabonik, Ginkocer, Psorid, Raricap, Serlift, and Onabet, among others. Its patient care initiatives (PCI) platform provides various healthcare solutions to its patients. The Company has a manufacturing plant located in Guwahati, Assam.
- Revenue in INR (TTM)30.78bn
- Net income in INR4.31bn
- Incorporated2007
- Employees3.56k
- LocationEris Lifesciences Ltd7th Floor, Commerce House IV,,Beside Shell Petrol Pump, 100 Feet Road,AHMEDABAD 380054IndiaIND
- Phone+91 7 969661000
- Fax+91 7 930179404
- Websitehttps://eris.co.in/
More ▼
Mergers & acquisitions
| Acquired company | ERIS:NSI since announced | Transaction value |
|---|---|---|
| Swiss Parenterals Ltd | -12.61% | 42.88m |
Data delayed at least 15 minutes, as of Mar 05 2026 09:59 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alivus Life Sciences Ltd | 25.12bn | 5.44bn | 111.80bn | 2.20k | 20.59 | -- | 18.18 | 4.45 | 44.23 | 44.23 | 204.37 | -- | -- | -- | -- | 11,403,810.00 | -- | 17.43 | -- | 23.95 | 57.08 | 53.29 | 21.64 | 20.24 | -- | 133.39 | -- | 27.09 | 4.54 | 9.20 | 3.13 | 9.18 | 26.57 | -- |
| Cohance Lifesciences Ltd | 20.51bn | 2.02bn | 114.06bn | 1.21k | 51.39 | -- | 33.21 | 5.56 | 5.80 | 5.80 | 58.32 | -- | -- | -- | -- | 16,926,160.00 | -- | 18.62 | -- | 20.90 | 71.62 | 60.82 | 8.80 | 30.28 | -- | 7.07 | -- | 15.59 | 13.91 | 7.51 | -10.79 | -3.31 | 9.39 | -- |
| Caplin Point Laboratories Ltd | 20.89bn | 6.14bn | 125.46bn | 990.00 | 20.51 | -- | 18.10 | 6.00 | 80.49 | 80.49 | 274.05 | -- | -- | -- | -- | 21,105,860.00 | -- | 19.10 | -- | 21.90 | 60.67 | 54.95 | 29.77 | 26.11 | -- | 1,127.02 | -- | 8.93 | 14.37 | 17.55 | 17.33 | 20.06 | 20.07 | 19.14 |
| Concord Biotech Ltd | 11.59bn | 3.12bn | 125.67bn | 1.57k | 40.43 | -- | 33.01 | 10.85 | 29.71 | 29.71 | 110.27 | -- | -- | -- | -- | 7,375,525.00 | -- | 18.47 | -- | 20.61 | 57.97 | 67.80 | 26.85 | 30.22 | -- | -- | -- | 20.68 | 18.01 | 18.56 | 20.62 | 17.06 | -6.49 | -- |
| Jubilant Pharmova Ltd | 79.18bn | 4.33bn | 132.13bn | 978.00 | 30.64 | -- | 15.58 | 1.67 | 27.23 | 27.23 | 498.28 | -- | -- | -- | -- | 80,965,230.00 | -- | 3.37 | -- | 4.02 | 67.71 | 64.54 | 5.42 | 5.64 | -- | 4.06 | -- | 21.60 | 7.93 | 3.90 | 988.72 | 6.73 | 14.21 | 0.00 |
| Alembic Pharmaceuticals Ltd | 72.67bn | 6.29bn | 137.26bn | 16.57k | 21.78 | -- | 14.84 | 1.89 | 32.06 | 32.06 | 370.42 | -- | -- | -- | -- | 4,385,258.00 | -- | 9.51 | -- | 12.59 | 72.71 | 65.30 | 8.61 | 10.84 | -- | 8.89 | -- | 33.08 | 7.12 | 7.69 | -5.26 | -6.78 | -5.17 | 9.46 |
| Granules India Ltd | 50.92bn | 5.45bn | 137.37bn | 4.07k | 24.66 | -- | 16.68 | 2.70 | 22.48 | 22.48 | 209.84 | -- | -- | -- | -- | 12,524,500.00 | -- | 10.20 | -- | 15.66 | 64.46 | 50.89 | 10.71 | 11.64 | -- | 6.98 | -- | 8.72 | -0.5494 | 11.52 | 23.74 | 9.64 | 25.38 | 8.45 |
| Neuland Laboratories Ltd | 15.75bn | 1.79bn | 163.91bn | 1.80k | 91.51 | -- | 62.40 | 10.41 | 139.62 | 139.62 | 1,227.57 | -- | -- | -- | -- | 8,755,392.00 | -- | 11.09 | -- | 14.93 | 49.33 | 49.56 | 11.37 | 14.20 | -- | 12.29 | -- | 6.80 | -5.24 | 14.13 | -13.32 | 45.82 | 33.44 | 43.10 |
| Natco Pharma Ltd | 45.60bn | 15.57bn | 170.71bn | 4.20k | 10.96 | -- | 9.49 | 3.74 | 86.94 | 86.94 | 254.62 | -- | -- | -- | -- | 10,860,210.00 | -- | 15.82 | -- | 18.14 | 82.79 | 75.22 | 33.87 | 30.39 | -- | 44.51 | -- | 12.09 | 10.77 | 18.26 | 35.81 | 32.55 | 7.37 | -2.33 |
| Eris Lifesciences Ltd | 30.78bn | 4.31bn | 188.13bn | 3.56k | 42.96 | -- | 24.81 | 6.11 | 31.61 | 31.61 | 225.62 | -- | -- | -- | -- | 8,651,377.00 | -- | 9.98 | -- | 13.50 | 74.64 | 77.74 | 15.28 | 20.85 | -- | 4.06 | -- | -- | 44.02 | 21.92 | -10.24 | 3.48 | 0.4868 | -- |
| Piramal Pharma Ltd | 88.71bn | -1.64bn | 201.56bn | 7.13k | -- | -- | 29.13 | 2.27 | -1.26 | -1.26 | 66.90 | -- | -- | -- | -- | 12,449,300.00 | -- | -- | -- | -- | 64.63 | -- | -1.84 | -- | -- | 0.5519 | -- | -- | 11.99 | -- | 411.39 | -- | -- | -- |
| Wockhardt Ltd | 31.51bn | 220.00m | 209.66bn | 2.30k | 975.20 | -- | 89.22 | 6.65 | 1.32 | 1.32 | 194.54 | -- | -- | -- | -- | 13,723,870.00 | -- | -4.37 | -- | -7.67 | 65.92 | 56.50 | 0.2539 | -11.98 | -- | 1.23 | -- | -- | 7.65 | 1.15 | 89.85 | -- | 16.19 | -- |
| Sai Life Sciences Ltd | 21.70bn | 3.33bn | 212.68bn | 3.40k | 64.91 | -- | 43.23 | 9.80 | 15.47 | 15.47 | 100.85 | -- | -- | -- | -- | 6,380,065.00 | -- | -- | -- | -- | 73.41 | -- | 15.34 | -- | -- | 10.74 | -- | -- | 15.66 | -- | 105.45 | -- | -- | -- |
| Astrazeneca Pharma India Ltd | 21.77bn | 2.01bn | 217.54bn | 802.00 | 108.26 | -- | 90.06 | 9.99 | 80.38 | 80.38 | 871.22 | -- | -- | -- | -- | 27,150,250.00 | -- | 11.06 | -- | 18.24 | 42.78 | 49.98 | 9.23 | 9.43 | -- | 78.86 | -- | 38.57 | 32.48 | 15.59 | -28.34 | 9.89 | -34.23 | 100.00 |
| Pfizer Ltd | 24.82bn | 8.54bn | 222.63bn | 1.60k | 26.08 | -- | 24.39 | 8.97 | 186.60 | 186.60 | 542.67 | -- | -- | -- | -- | 15,533,980.00 | -- | 15.22 | -- | 18.50 | 65.10 | 61.73 | 34.39 | 25.99 | -- | 83.13 | -- | 50.95 | 4.02 | 1.18 | 39.23 | 8.56 | -6.02 | 28.47 |
| Emcure Pharmaceuticals Ltd | 88.50bn | 8.70bn | 278.11bn | 6.73k | 31.96 | -- | 21.39 | 3.14 | 45.91 | 45.91 | 467.02 | -- | -- | -- | -- | 13,148,240.00 | -- | 8.47 | -- | 15.86 | 59.93 | 59.30 | 10.11 | 8.99 | -- | 30.68 | -- | 0.00 | 18.59 | 9.36 | 36.76 | 52.13 | 21.35 | -- |
Data as of Mar 05 2026. Currency figures normalised to Eris Lifesciences Ltd's reporting currency: Indian Rupee INR
20.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 11.53m | 8.46% |
| Franklin Templeton Asset Management (India) Pvt Ltd.as of 30 Jan 2026 | 4.86m | 3.57% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Jan 2026 | 2.98m | 2.19% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 1.69m | 1.24% |
| Templeton Asset Management Ltd.as of 31 Jan 2026 | 1.38m | 1.01% |
| DSP Asset Managers Pvt. Ltd.as of 31 Jan 2026 | 1.23m | 0.90% |
| Bank of India Investment Managers Pvt Ltd.as of 31 Jan 2026 | 1.04m | 0.76% |
| HSBC Asset Management (India) Pvt Ltd.as of 31 Jan 2026 | 980.80k | 0.72% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Jan 2026 | 837.44k | 0.62% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 713.82k | 0.52% |
More ▼
Data from 31 Dec 2025 - 15 Feb 2026Source: FactSet Research Systems Inc.
